Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

Publication | Closed Access

DOI

120

Citations

References

2019

Year

Yeon Hee Park, Tae‐Yong Kim, Gun Min Kim, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Kyoung Eun Lee, Hee Kyung Ahn, Moon Hee Lee, Hee‐Jun Kim,

The Lancet Oncology

Breast OncologyMedicinePharmacologyGynecologyBreast CancerPharmacotherapyPremenopausal WomenCancer TreatmentOncologyRadiation OncologyEndocrine-related Cancer